333
Participants
Start Date
December 22, 2022
Primary Completion Date
October 11, 2023
Study Completion Date
October 11, 2023
Phentolamine Opthalmic Solution 0.75%
phentolamine ophthalmic solution 0.75% (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
Placebo
Vehicle for Phentolamine Ophthalmic Solution
Low dose pilocarpine
Pilocarpine hydrochloride ophthalmic solution 0.4%
Low dose pilocarpine vehicle
Vehicle for low dose pilocarpine
Smithtown, NY, Smithtown
Rochester, NY, Rochester
Cranberry Township, PA, Cranberry Township
New Freedom, PA, New Freedom
Garner, NC, Garner
Roswell, GA, Roswell
Longwood, FL, Longwood
Delray Beach, FL, Delray Beach
Memphis, TN, Memphis
Athens, OH, Athens
Bloomington, MN, Bloomington
Sioux Falls, SD, Sioux Falls
Fargo, ND, Fargo
Lake Villa, IL, Lake Villa
Chesterfield, MO, Chesterfield
Saint Louis, MO, St Louis
Kansas City, MO, Kansas City
Shawnee Mission, KS, Shawnee Mission
Pittsburg, KS, Pittsburg
Austin, TX, Austin
Houston, TX, Houston
San Antonio, TX, San Antonio
Phoenix, AZ, Phoenix
Northridge, CA, Northridge
Azusa, CA, Azusa
Newport Beach, CA, Newport Beach
Lead Sponsor
Ocuphire Pharma, Inc.
INDUSTRY